Dmitrij Hristodorov PhD
General Partner
Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach of reprogramming recombinases.
Seamless Therapeutics' platform has succeeded in reprogramming site specific recombinases to any given target sequence which can be a disease target, for example, and make a range of specific changes including inversion, excision, exchange, and insertion from small to larger DNA fragments.
Recombinases are a class of enzymes that have been widely used in scientific research for decades to precisely modify the genome of model organisms but until now have been limited in their applicability as a therapeutic due to their limited programmability to act on new target sites. The company is applying its proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.
Human Health
DE
Seamless Therapeutics GmbH
Tatzberg 47/49
01307 Dresden
Germany
US
Seamless Therapeutics, Inc.
10 Maguire Rd
Building 2 Suite 100
Lexington, MA 02421
USA
Industry
Biotech
Status
Current
Location
Germany
At Seamless Therapeutics, I’m inspired by the steady progress we’re making toward a future where precise genome editing is not just possible, but targeted and therapeutic in its application. By advancing recombinase technologies to act with specificity in the human genome, we’re opening doors to transformative therapies for patients who need them most. It’s exciting to be working with our colleagues at Forbion, whose support and experience is instrumental in leading the company to our goal of turning scientific innovation into meaningful impact.Albert Seymour
CEO
$12.5m
seed financing
Forbion team
Tim Lohoff PhD
Principal